De-Risking Phase 3 Rheumatoid Arthritis Trials with Model-Based Meta-Analysis (MBMA) Case Study De-Risking Phase 3 Rheumatoid Arthritis Trials with Model-Based Meta-Analysis (MBMA) Learn how Model-based meta-analysis (MBMA) helped optimize Phase 3 trial design, dose selection, and development…Danielle Pillsbury2026年8月28日
The five drug development questions that bring sponsors to pharmacometrics Blog The five drug development questions that bring sponsors to pharmacometrics Sponsors rarely come to pharmacometrics because they need a model. They come with a development…Rik de Greef2026年8月24日
Beyond Trial and Error: Model-Informed Formulation Development in Practice Webinar Beyond Trial and Error: Model-Informed Formulation Development in Practice Siri Kalyan Chirumamilla2026年8月24日
MBMA data curation: How AI and expert meta-analysts get it right, fast Blog MBMA data curation: How AI and expert meta-analysts get it right, fast In MBMA, the data layer is the real bottleneck. See how AI and expert meta-analysts…Matt Zierhut, PhD MBA2026年8月14日
Transforming drug interaction evaluation workflows with DIDB Webinar Transforming drug interaction evaluation workflows with DIDB Ichiko Petrie, PharmD2026年8月14日
A model-informed approach to radioligand therapy dosing under Project Optimus Blog A model-informed approach to radioligand therapy dosing under Project Optimus Explore how targeted radionuclide therapy dosing uses QSP, biologically effective dose (BED), and exposure-response modeling…Hunter Stephens, PhD2026年8月13日
Managing drug-drug interaction (DDI) risk for patients in clinical trials White Paper Managing drug-drug interaction (DDI) risk for patients in clinical trials Discover how DIDB® helps clinical teams assess drug-drug interaction risk, develop prohibited medication lists, &…Katie Owens, PhD2026年8月12日
Tailwinds for MIDD: What to Know About the Changing Regulatory Landscape Live Events Tailwinds for MIDD: What to Know About the Changing Regulatory Landscape 2026年9月30日 - 11:30 PM – 2:00 PMCertara2026年8月12日
Advances and Challenges in Model-Informed Precision Dosing of Antimicrobials for Pediatric Patients Publication Advances and Challenges in Model-Informed Precision Dosing of Antimicrobials for Pediatric Patients Explore advances in model-informed precision dosing (MIPD) for pediatric antimicrobial therapy, including population PK modeling,…Certara2026年7月29日
Conditional activation of IL-12 through a Fibronectin-EDB dependent switch gate Publication Conditional activation of IL-12 through a Fibronectin-EDB dependent switch gate See how QSP modeling guided the design of a reversible antibody switch that unmasks IL-12…Certara2026年7月24日